ONC – beone medicines ltd. - american depositary shares (US:NASDAQ)
Stock Stats
News
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
BeOne Medicines (NASDAQ:ONC) was given a new $400.00 price target on by analysts at Truist Financial Corporation.
BeOne Medicines (NASDAQ:ONC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Royal Bank Of Canada from $395.00 to $408.00. They now have an "outperform" rating on the stock.
Form 4 BeOne Medicines Ltd. For: Nov 26 Filed by: Sanders Corazon (Corsee) D.
Form 4 BeOne Medicines Ltd. For: Nov 17 Filed by: Wu Xiaobin
Form 4 BeOne Medicines Ltd. For: Nov 12 Filed by: Wu Xiaobin
Form 4 BeOne Medicines Ltd. For: Nov 12 Filed by: Lee Chan Henry
Form 4 BeOne Medicines Ltd. For: Nov 07 Filed by: Wang Xiaodong
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.